MCID: CNT016
MIFTS: 50

Central Retinal Vein Occlusion

Categories: Cardiovascular diseases, Rare diseases

Aliases & Classifications for Central Retinal Vein Occlusion

MalaCards integrated aliases for Central Retinal Vein Occlusion:

Name: Central Retinal Vein Occlusion 12 55 51 14 69
Crvo 55

Characteristics:

Orphanet epidemiological data:

55
central retinal vein occlusion
Prevalence: 1-5/10000 (Europe); Age of onset: Adult,Elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:2450
ICD10 32 H34.81
ICD9CM 34 362.35
NCIt 46 C118859
SNOMED-CT 64 193378003 68478007
Orphanet 55 ORPHA411527
UMLS via Orphanet 70 C0154841
ICD10 via Orphanet 33 H34.8
UMLS 69 C0154841

Summaries for Central Retinal Vein Occlusion

MalaCards based summary : Central Retinal Vein Occlusion, also known as crvo, is related to macular retinal edema and macular holes. An important gene associated with Central Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 72 The central retinal vein is the venous equivalent of the central retinal artery and, like that blood... more...

Related Diseases for Central Retinal Vein Occlusion

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Central Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 30.8 IL6 SERPINF1 VEGFA
2 macular holes 30.3 SERPINF1 VEGFA
3 purpura 30.0 APOH F2 SERPINC1
4 factor xii deficiency 29.9 APOH F5 SERPINC1
5 exfoliation syndrome 29.9 LOXL1 MTHFR
6 hemophilia b 29.8 F2 SERPINC1
7 pulmonary hypertension 29.7 IL6 SERPINC1 VEGFA
8 thrombocytosis 29.6 F2 IL6 SERPINC1
9 branch retinal artery occlusion 29.6 APOH F2 MTHFR SERPINC1
10 retinal artery occlusion 29.5 APOH F2 F5 MTHFR SERPINC1
11 von willebrand's disease 29.4 F2 F5
12 protein s deficiency 29.3 APOH F2 F5 MTHFR SERPINC1
13 ischemic optic neuropathy 29.3 APOH F2 F5 MTHFR SERPINC1
14 protein c deficiency 29.3 F2 F5 MTHFR SERPINC1
15 nonarteritic anterior ischemic optic neuropathy 29.3 F2 F5 MTHFR SERPINC1
16 thrombophilia 29.3 APOH F2 F5 MTHFR SERPINC1
17 eclampsia 29.3 F2 F5 MTHFR SERPINC1
18 sneddon syndrome 29.2 APOH F2 F5 SERPINC1
19 vascular disease 29.1 APOH F5 MTHFR SERPINC1 VEGFA
20 thrombosis 29.1 APOH F2 F5 MTHFR SERPINC1
21 antithrombin iii deficiency 28.8 APOH F2 F5 MTHFR SERPINC1
22 antiphospholipid syndrome 28.8 APOH F2 F5 MTHFR SERPINC1
23 retinal vein occlusion 28.5 APOH F2 F5 IL6 LOXL1 MTHFR
24 retinal vascular occlusion 28.4 APOH F2 F5 MTHFR SERPINC1 VEGFA
25 hellp syndrome 28.3 APOH F2 F5 IL6 MTHFR SERPINC1
26 pre-eclampsia 27.8 APOH F2 F5 IL6 MTHFR SERPINC1
27 retinitis 11.2
28 hydrops, lactic acidosis, and sideroblastic anemia 10.9
29 endotheliitis 10.5
30 inferior vena cava interruption 10.5 F5 MTHFR
31 amaurosis fugax 10.5 F5 MTHFR
32 hemifacial spasm 10.4 MTHFR VEGFA
33 chorioretinitis 10.4
34 may-thurner syndrome 10.4 APOH F5
35 acanthamoeba keratitis 10.4 APOH F5
36 neovascular glaucoma 10.4
37 sticky platelet syndrome 10.4 F5 SERPINC1
38 carotid artery occlusion 10.3 APOH F5
39 osteoporotic fracture 10.3 IL6 MTHFR
40 schizencephaly 10.3 F5 MTHFR
41 meningococcemia 10.3 F5 SERPINC1
42 gastroschisis 10.3 IL6 MTHFR
43 critical limb ischemia 10.3 IL6 VEGFA
44 legg-calve-perthes disease 10.3 F5 SERPINC1
45 choroiditis 10.3
46 ischemic heart disease 10.3 IL6 MTHFR
47 encephalomalacia 10.3 IL6 MTHFR
48 spinal disease 10.3 IL6 VEGFA
49 poems syndrome 10.3 IL6 VEGFA
50 arteriovenous fistula 10.2 APOH IL6

Comorbidity relations with Central Retinal Vein Occlusion via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Central Retinal Vein Occlusion:



Diseases related to Central Retinal Vein Occlusion

Symptoms & Phenotypes for Central Retinal Vein Occlusion

MGI Mouse Phenotypes related to Central Retinal Vein Occlusion:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 SERPINF1 F5 VEGFA IL6 LOXL1 SERPINC1
2 homeostasis/metabolism MP:0005376 9.86 F2 F5 VEGFA IL6 LOXL1 MTHFR
3 digestive/alimentary MP:0005381 9.72 SERPINF1 F2 VEGFA IL6 LOXL1
4 integument MP:0010771 9.63 F2 F5 VEGFA IL6 LOXL1 MTHFR
5 nervous system MP:0003631 9.56 VEGFA F5 IL6 LOXL1 MTHFR SERPINC1
6 reproductive system MP:0005389 9.17 VEGFA IL6 LOXL1 MTHFR SERPINC1 F2

Drugs & Therapeutics for Central Retinal Vein Occlusion

Drugs for Central Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
4
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
5
Lactitol Investigational Phase 4 585-86-4 3871
6 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
7 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
9 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
10 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
11 Hormones Phase 4,Phase 2,Phase 3,Phase 1
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
13 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
14 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Phase 1
15 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Phase 1
16 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Phase 1
17 Endothelial Growth Factors Phase 4,Phase 3,Phase 1,Phase 2
18 Mitogens Phase 4,Phase 3,Phase 1,Phase 2
19 Antiemetics Phase 4,Phase 2,Phase 3
20 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
21 Autonomic Agents Phase 4,Phase 2,Phase 3
22 BB 1101 Phase 4,Phase 2,Phase 3
23 Dexamethasone acetate Phase 4,Phase 2,Phase 3 1177-87-3
24 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
25 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
26 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
27
protease inhibitors Phase 4,Phase 2,Phase 3
28 Dexamethasone 21-phosphate Phase 4
29 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
30 histidine Nutraceutical Phase 4
31
Povidone-iodine Approved Phase 3 25655-41-8
32
Iodine Approved, Investigational Phase 3 7553-56-2 807
33
Povidone Approved Phase 3 9003-39-8
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
35
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
36
Nicotinamide Approved, Investigational, Nutraceutical Phase 2, Phase 3 98-92-0 936
37 Anticholesteremic Agents Phase 3
38 Antimetabolites Phase 3,Phase 2
39 Atorvastatin Calcium Phase 3 134523-03-8
40 Calcium, Dietary Phase 3
41 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
42 Hypolipidemic Agents Phase 3,Phase 2
43 Lipid Regulating Agents Phase 3,Phase 2
44 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
45 Antibiotics, Antitubercular Phase 3
46 Micronutrients Phase 2, Phase 3
47 Nicotinic Acids Phase 2, Phase 3
48 Ophthalmic Solutions Phase 2, Phase 3,Phase 1
49 Tetrahydrozoline Phase 2, Phase 3
50 Trace Elements Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 95)

# Name Status NCT ID Phase Drugs
1 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
2 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4 Aflibercept
3 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
4 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
5 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
6 Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion Completed NCT01448018 Phase 4 ranibizumab
7 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
8 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4 0.5mg Ranibizumab
9 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4 bevacizumab
10 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4 Dexamethasone
11 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
12 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Recruiting NCT02800642 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
13 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Active, not recruiting NCT02274259 Phase 4 Aflibercept;Ranibizumab
14 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4 Aflibercept
15 Atorvastatin for the Treatment of Retinal Vein Occlusion Unknown status NCT00517257 Phase 3 Atorvastatin;Placebo
16 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3 bevacizumab;Sham bevacizumab injection
17 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT00943072 Phase 3 Sham
18 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01976312 Phase 3 Ranibizumab 0.5 mg
19 Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion Completed NCT01295112 Phase 2, Phase 3 Active bevacizumab and Sham dexamethasone;Active bevacizumab and Active dexamethasone
20 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT01535261 Phase 3 Ranibizumab 0.5 mg/0.05 ml
21 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
22 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01396083 Phase 3 Ranibizumab;Dexamethasone implant and sham injections
23 A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) Completed NCT00485836 Phase 3 Sham injection;Ranibizumab injection 0.3 mg;Ranibizumab injection 0.5 mg
24 The ROVO Study: Radial Optic Neurotomy for CVO Completed NCT00532142 Phase 2, Phase 3 Intravitreal Triamcinolone
25 A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO Completed NCT00567697 Phase 3 ranibizumab;ranibizumab
26 Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Completed NCT01377597 Phase 3 ranibizumab
27 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study Completed NCT00105027 Phase 3 intravitreal triamcinolone injection;intravitreal triamcinolone injection
28 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed NCT01198327 Phase 3 ranibizumab
29 Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions Completed NCT00500045 Phase 2, Phase 3 nicotinic acid
30 Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Completed NCT00970957 Phase 3 Avastin Intravitreal Injection;Sham Avastin Intravitreal Injection
31 Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage Completed NCT00106132 Phase 3 Triamcinolone Acetonide
32 Bevacizumab Versus Ranibizumab for Diabetic Retinopathy Completed NCT00545870 Phase 3 bevacizumab;Ranibizumab
33 Ozurdex for Retinal Vein Occlusion Study (ORVO Study) Completed NCT01790685 Phase 2, Phase 3 dexamethasone implant
34 Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Recruiting NCT03223714 Phase 3 Conbercept Ophthalmic Injection;sham injection
35 DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME Recruiting NCT03321513 Phase 3 intravitreous aflibercept;Bevacizumab + Deferred Aflibercept Group
36 Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Active, not recruiting NCT01969708 Phase 3 aflibercept;bevacizumab
37 Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Not yet recruiting NCT02947867 Phase 2, Phase 3 aganirsen
38 Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Unknown status NCT02405741 Phase 2
39 Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO) Unknown status NCT01178697 Phase 2 Bevasizumab;Triamcinolone Acetonide
40 Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT01123564 Phase 2 ranibizumab
41 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
42 Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion Completed NCT02614937 Phase 1, Phase 2 ranibizumab;Squalamine Lactate Ophthalmic Solution, 0.2%
43 Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Completed NCT01724554 Phase 1, Phase 2 Intravitreal Aflibercept Injection
44 Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT00088283 Phase 2 pegaptanib sodium
45 Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Completed NCT01471691 Phase 1, Phase 2 ranibizumab 0.5mg;ranibizumab 1.0mg
46 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
47 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
48 Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions Completed NCT01003106 Phase 1, Phase 2 Ranibizumab 0.5mg (monthly);Ranibizumab 2.0mg (monthly);Pro re nata (prn) ranibizumab
49 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Recruiting NCT02957760 Phase 2 Hydroxycarbamid
50 Phase I/II Trial to Find Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLT) of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Recruiting NCT02006147 Phase 1, Phase 2 TLC399(ProDex)

Search NIH Clinical Center for Central Retinal Vein Occlusion

Genetic Tests for Central Retinal Vein Occlusion

Anatomical Context for Central Retinal Vein Occlusion

MalaCards organs/tissues related to Central Retinal Vein Occlusion:

38
Eye, Retina, Endothelial, Bone, Myeloid, Colon, Liver

Publications for Central Retinal Vein Occlusion

Articles related to Central Retinal Vein Occlusion:

(show top 50) (show all 676)
# Title Authors Year
1
Central retinal vein occlusion in temporal arteritis: red sign or red herring? ( 29361164 )
2018
2
Effects of Dexamethasone Implant on Multifocal Electroretinography in Central Retinal Vein Occlusion. ( 29403585 )
2018
3
YC-1 Inhibits VEGF and Inflammatory Mediators Expression on Experimental Central Retinal Vein Occlusion in Rhesus Monkey. ( 29364731 )
2018
4
Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion. ( 29447089 )
2018
5
Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab. ( 29426292 )
2018
6
Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. ( 29185099 )
2018
7
Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion. ( 28591282 )
2017
8
Central Retinal Vein Occlusion in 2 Patients Using Antipsychotic Drugs. ( 28924438 )
2017
9
"Dye front reciprocation" in combined central retinal vein occlusion with cilioretinal artery infarction. ( 29133654 )
2017
10
Cilioretinal Artery Occlusion Combined with Central Retinal Vein Occlusion: What Is the Best Imaging Modality for the Follow-Up? ( 29430314 )
2017
11
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. ( 28492910 )
2017
12
Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature. ( 28603574 )
2017
13
Central retinal vein occlusion after coronary artery bypass surgery: A case report. ( 28605930 )
2017
14
Management of macular edema due to central retinal vein occlusion - The role of aflibercept. ( 29018760 )
2017
15
Metamorphopsia associated with central retinal vein occlusion. ( 29049410 )
2017
16
Retinal Nonperfusion in the Posterior Pole Is Associated With Increased Risk of Neovascularization in Central Retinal Vein Occlusion. ( 28739419 )
2017
17
Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections. ( 28946138 )
2017
18
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study. ( 28620704 )
2017
19
CONN SYNDROME PRESENTING AS CENTRAL RETINAL VEIN OCCLUSION. ( 28644176 )
2017
20
Predictive Value of Baseline Biochemical Parameters for Clinical Response of Macular Edema to Bevacizumab in Eyes With Central Retinal Vein Occlusion: A Retrospective Analysis. ( 29082677 )
2017
21
EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. ( 28767552 )
2017
22
Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial. ( 28979743 )
2017
23
High Altitude Retinopathy Presenting as Central Retinal Vein Occlusion in a Soldier. ( 29185408 )
2017
24
RETINAL MICROVASCULATURE AND VISUAL ACUITY AFTER INTRAVITREAL AFLIBERCEPT IN EYES WITH CENTRAL RETINAL VEIN OCCLUSION: An Optical Coherence Tomography Angiography Study. ( 28902097 )
2017
25
Assessment of ischemia in acute central retinal vein occlusion from inner retinal reflectivity on spectral domain optical coherence tomography. ( 28053503 )
2017
26
A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial. ( 28302155 )
2017
27
Central Retinal Vein Occlusion-like Appearance: A Precursor Stage in Evolution of Frosted Branch Angiitis. ( 29090058 )
2017
28
Short-term results of endovascular surgery with tissue plasminogen activator injection for central retinal vein occlusion. ( 28803326 )
2017
29
Unilateral Adult Xanthogranulomatous Infiltration of the Conjunctiva, Limbus and Sclera Leading to a Combined Ophthalmic Artery and Central Retinal Vein Occlusion. ( 29299083 )
2017
30
One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion. ( 29260119 )
2017
31
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: special remarks of the RANIDEX study. ( 28752369 )
2017
32
LABORATORY EVALUATION OF HYPERCOAGULABLE STATES IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION WHO ARE LESS THAN 56 YEARS OF AGE. ( 28613222 )
2017
33
BARTONELLA HENSELAE NEURORETINITIS ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION, CHOROIDAL ISCHEMIA, AND ISCHEMIC OPTIC NEUROPATHY. ( 28700390 )
2017
34
Treatment of Macular Edema Due to Central Retinal Vein Occlusion: Another Score for Repackaged Bevacizumab. ( 28492939 )
2017
35
EVALUATION OF MACULAR ISCHEMIA IN EYES WITH CENTRAL RETINAL VEIN OCCLUSION: An Optical Coherence Tomography Angiography Study. ( 28671896 )
2017
36
BETTER PROGNOSIS FOR EYES WITH PRESERVED FOVEAL DEPRESSION AFTER INTRAVITREAL RANIBIZUMAB INJECTION FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. ( 28538263 )
2017
37
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study. ( 28744657 )
2017
38
Frosted Branch Angiitis Secondary to Familial Mediterranean Fever Resembling Central Retinal Vein Occlusion. ( 28044118 )
2016
39
MACULAR PERIVENOUS RETINAL WHITENING AND PRESUMED RETINO-CILIARY SPARING IN A RECURRENT CENTRAL RETINAL VEIN OCCLUSION ASSOCIATED WITH THE ANTIPHOSPHOLIPID SYNDROME AND CRYOGLOBULINEMIA. ( 27902540 )
2016
40
BILATERAL CENTRAL RETINAL VEIN OCCLUSIONS IN A YOUNG PATIENT WITH A HISTORY OF EOSINOPHILIC PNEUMONIA AND THALAMIC STROKE. ( 28045864 )
2016
41
Comment on: 'Central retinal vein occlusion: modifying current treatment protocols'. ( 27101747 )
2016
42
Central Retinal Artery Occlusion With Subsequent Central Retinal Vein Occlusion in Biopsy-Proven Giant Cell Arteritis. ( 27261946 )
2016
43
Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion. ( 27567889 )
2016
44
Optical Coherence Tomography Angiography in Central Retinal Vein Occlusion: Correlation Between the Foveal Avascular Zone and Visual Acuity. ( 27409478 )
2016
45
Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion. ( 26949616 )
2016
46
Bilateral Central Retinal Vein Occlusion as Presenting Feature of Chronic Myeloid Leukemia. ( 27555710 )
2016
47
Fernlike Maculopathy in a Patient With Central Retinal Vein Occlusion. ( 27281739 )
2016
48
Long-Term Functional and Anatomical Outcome of Radial Optic Neurotomy for Central Retinal Vein Occlusion. ( 27116505 )
2016
49
A Rare Cause of Unilateral Central Retinal Vein Occlusion in a Young Patient: Type III Mixed Cryoglobulinemia. ( 27418988 )
2016
50
Central retinal vein occlusion after plateletpheresis. ( 27264010 )
2016

Variations for Central Retinal Vein Occlusion

Expression for Central Retinal Vein Occlusion

Search GEO for disease gene expression data for Central Retinal Vein Occlusion.

Pathways for Central Retinal Vein Occlusion

GO Terms for Central Retinal Vein Occlusion

Cellular components related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 APOH F2 F5 IL6 LOXL1 SERPINC1
2 endoplasmic reticulum lumen GO:0005788 9.46 F2 F5 IL6 SERPINC1
3 extracellular space GO:0005615 9.23 APOH F2 F5 IL6 LOXL1 SERPINC1

Biological processes related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.65 F2 F5 SERPINC1
2 platelet degranulation GO:0002576 9.54 APOH F5 VEGFA
3 blood circulation GO:0008015 9.52 F5 MTHFR
4 lactation GO:0007595 9.51 SERPINC1 VEGFA
5 acute-phase response GO:0006953 9.49 F2 IL6
6 negative regulation of endothelial cell migration GO:0010596 9.46 APOH SERPINF1
7 blood coagulation, intrinsic pathway GO:0007597 9.43 APOH F2
8 positive regulation of blood coagulation GO:0030194 9.4 APOH F2
9 hemostasis GO:0007599 9.33 F2 F5 SERPINC1
10 negative regulation of fibrinolysis GO:0051918 9.32 APOH F2
11 positive regulation of STAT protein import into nucleus GO:2000366 9.26 F2 IL6
12 cellular protein metabolic process GO:0044267 9.26 F2 F5 IL6 SERPINC1
13 regulation of blood coagulation GO:0030193 8.8 APOH F2 SERPINC1

Molecular functions related to Central Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 F2 IL6 VEGFA
2 heparin binding GO:0008201 8.92 APOH F2 SERPINC1 VEGFA

Sources for Central Retinal Vein Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....